Letter to the editors

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 5, 2002, Pages 1033-1034

  Klok, R M ^a   Brouwers, J R B J ^a   Van Den Berg, P B ^a   De Jong Van Den Berg, L T W ^a   Tolley, K ^b   Postma, M J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR; AMOXICILLIN; CLARITHROMYCIN; GASTROINTESTINAL AGENT; PROTON PUMP;

COST EFFECTIVENESS ANALYSIS; DRUG UTILIZATION; ERADICATION THERAPY; GASTROESOPHAGEAL REFLUX; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; LETTER; PRIORITY JOURNAL; COST BENEFIT ANALYSIS; DRUG ANTAGONISM; ECONOMICS; FACTUAL DATABASE; HELICOBACTER INFECTION; NETHERLANDS; NOTE;

AMOXICILLIN; CLARITHROMYCIN; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; GASTROINTESTINAL AGENTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; NETHERLANDS; PROTON PUMPS;

EID: 0036234581     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01246.x     Document Type: Letter

References (4)

1. Lack of symptom benefit following presumptive Helicobacter pylori eradication therapy in primary care
2. The InterAction Database: Synergy of science and practice in pharmacy
3. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection
4. Helicobacter pylori and gastroesophageal reflux disease. The bug may not be all bad